Medical Cannabis and Chronic Pain: What Authorized Canadian Patients Report
Last Updated: February 2026 | Reading Time: 4 minutes
Chronic pain is the single most common condition driving medical cannabis authorization in Canada. Among veterans specifically, Statistics Canada data indicate that approximately 41% of Regular Force veterans report living with chronic pain or discomfort. This article reviews what peer-reviewed research has found about medical cannabis and chronic pain in Canadian authorized patients, including the veteran and harm reduction populations.
The Canadian Authorized Patient Picture
The most comprehensive data on why Canadians access medical cannabis comes from a 2019 cross-sectional survey of 2,032 patients authorized under Canada’s federal medical cannabis program, conducted by Lucas, Baron & Jikomes and published in Harm Reduction Journal. The scale and source make it directly applicable to understanding the authorized patient population.
The study found that 83.7% of authorized patients reported pain and mental health conditions as their primary reasons for use — grouping chronic pain, arthritis, headache, mental health conditions, PTSD, and insomnia together. The researchers also documented substitution patterns: 44.5% of authorized patients reported substituting cannabis for alcohol, and 69.1% reported substituting it for prescription medications.
These substitution rates are patient-reported, not clinically validated as treatment outcomes. What they reflect is that a significant proportion of people who obtained medical authorization in Canada were already managing conditions through other substances, and shifted, either partially or fully, to cannabis once they had authorized access to a regulated supply.
Veterans and Chronic Pain: What Focus Groups Found
A 2023 qualitative study by Storey, Keeler-Villa, Harris, Anthonypillai, Tippin, Parihar & Rash, published in the Canadian Journal of Pain, conducted focus groups with 12 Canadian veterans living with pain who used VAC-authorized medicinal cannabis. Veterans reported using medicinal cannabis primarily for chronic pain, sleep disturbance, and emotional distress — often managing several of these simultaneously. Most had initiated cannabis use to manage symptoms of preexisting conditions and reported improvements in overall quality of life and replacing multiple pharmacological treatments.
Opioid Use and Cannabis: The Substitution Evidence
A 2023 cross-sectional study by Reddon, Lake, Socias, Hayashi, DeBeck, Walsh & Milloy, drawing on BCCSU cohort participants and published in the International Journal of Drug Policy, found that 57.6% of the 205 opioid users surveyed reported decreasing opioid use through cannabis. The study named High Hopes Foundation — the predecessor organization to High Hopes Research Society — among the free cannabis distribution programs that participants accessed. In adjusted analysis, the significant predictors of self-reported opioid reduction were using cannabis specifically to manage opioid cravings (aOR=2.13, p=0.032) and daily cannabis use (aOR=3.87, p=0.028).
This is a community sample, not a veteran-specific population. But opioid use is not uncommon among veterans managing chronic pain, and the mechanism — cannabis reducing the need for opioids in a population managing ongoing pain — is relevant across settings.
What the Research Does Not Show
The data from Lucas et al. (2019) are cross-sectional and self-reported. They describe what authorized patients say they are using cannabis for and what substitution patterns they observe in themselves — they do not establish clinical efficacy under controlled conditions. The findings of Reddon et al. (2023) are observational cohort data, subject to the limitations of self-report and selection effects.
The research establishes that chronic pain is the dominant use case among Canada’s authorized medical cannabis patients, that veterans with chronic pain are using cannabis at meaningful rates, and that substitution for opioids and prescription drugs is common in this population. It does not establish cannabis as a clinically validated first-line treatment for chronic pain.
Access for Canadian Veterans
Veterans Affairs Canada covers medical cannabis costs for eligible veterans, processed through Medavie Blue Cross. RCMP members, Canadian Armed Forces personnel, and those covered under the Interim Federal Health Program have similar coverage pathways. Authorization requires a prescription from a qualified healthcare provider.
This article summarizes published peer-reviewed research for informational purposes. It does not constitute medical advice. Medical cannabis requires authorization from a qualified healthcare provider. The research cited represents the findings of independent investigators and does not constitute a health claim about any specific product.
A 2019 survey of 2,032 authorized patients in Canada’s federal medical cannabis program found that 83.7% reported pain and mental health conditions as their primary reason for authorization, when those categories are grouped broadly. Chronic pain was the single most common individual condition.
The research does not support cannabis as a replacement for prescribed pain medication. However, a 2019 Canadian survey found that 69.1% of authorized patients reported substituting cannabis for prescription drugs, including opioids, benzodiazepines, and sleep medications. Substitution was self-reported and occurred alongside, not as a replacement for, clinical care. Any changes to prescribed medication should be discussed with a healthcare provider.
Yes, for eligible veterans. Veterans Affairs Canada reimburses authorized medical cannabis at up to $6.00 per gram through Medavie Blue Cross. Authorization requires a medical document specifying a daily gram amount and a qualifying condition, issued by a licensed healthcare practitioner.
A 2023 study by the BC Centre on Substance Use examined 205 opioid users across three longitudinal cohorts and found that 57.6% reported reducing opioid use through cannabis. In adjusted analysis, the strongest predictors of opioid reduction were using cannabis specifically to manage cravings and using cannabis daily, indicating that intentional, consistent use is the operative variable.
References
- Lucas, Baron & Jikomes (2019). Harm Reduction Journal, 16(1): 9. DOI: 10.1186/s12954-019-0278-6
- Reddon, Lake, Socias, Hayashi, DeBeck, Walsh & Milloy (2023). International Journal of Drug Policy. PMC10817207
- Storey, Tippin & Rash (2023). Canadian Journal of Pain, 7(1): 2232838. DOI: 10.1080/24740527.2023.2232838